Synthaverse received a permit from the District Construction Supervision Inspector in Lublin to use the research and development building as part of the Research and Development Center (CBR), the company announced.
The Research and Development Center is one of the company’s two strategic investments. The decision issued by the Lublin office allows for the formal use of the CBR building facility in accordance with its intended purpose. The next stages will be investor and final acceptance, it was announced.
“We received a positive decision from the District Construction Supervision Inspector in Lublin a little earlier than we originally expected. This is a very important milestone in the company’s development. The operation of a modern CBR will increase the competitiveness of our products and create new expansion opportunities. Now we are at the investor acceptance stage, after which the final acceptance will take place and then our Research and Development Center should be in full swing. In parallel, as planned, we are implementing the second of our strategic investments – the construction of the Onko BCG production plant. Since the beginning of the year, we have spent approximately PLN 70 million on both projects,” said Mieczysław Starkowicz, president of Synthaverse, quoted in the release.
The Lublin company created a Research and Development Center with the aim of improving technologies related to vaccinology in the prevention of tuberculosis and immunology in the treatment of cancer.
“The research conducted in our CBR is intended to result in the implementation of innovative products on the market on an international scale. At the same time, by developing improved Onko BCG medicinal products and BCG vaccines, they are to respond to patients’ needs,” added the president.
Synthaverse (formerly Biomed Lublin Wytwórnia Surowic i Szczepionek) is a Polish pharmaceutical company operating since 1944. The company produces medicinal preparations (prescription drugs, medical devices and laboratory reagents used in biochemical and medical laboratories). The company has been listed on the main market of the WSE since 2015; is included in the mWIG40 index.